Indications and usage
LOVENOX® (enoxaparin sodium injection) is indicated for the prophylaxis
of deep vein thrombosis, which may lead to pulmonary embolism:
- in patients undergoing abdominal surgery who are at risk for thromboembolic complications;
- in patients undergoing hip-replacement surgery, during and following hospitalization;
- in patients undergoing knee-replacement surgery;
- in medical patients who are at risk for thromboembolic complications due to severely
restricted mobility during acute illness.
LOVENOX® is indicated for:
- the inpatient treatment of acute deep vein thrombosis, with or without
pulmonary embolism, when administered in conjunction with warfarin sodium;
- the outpatient treatment of acute deep vein thrombosis, without pulmonary
embolism, when administered in conjunction with warfarin sodium.
LOVENOX® is indicated for the prophylaxis of ischemic complications of unstable
angina and non–Q-wave myocardial infarction, when concurrently administered with
aspirin.
LOVENOX® has been shown to reduce the rate of the combined endpoint of recurrent
myocardial infarction or death in patients with acute STEMI receiving prophylaxis
and being managed medically or with percutaneous coronary intervention (PCI).
Please see Full Prescribing Information including
boxed WARNING, for additional important
information.
Important Safety Information
LOVENOX® Full Prescribing Information
Certain procedures, called "epidural/spinal anesthesia" and "spinal puncture," may
be used as a normal part of hospitalization. Patients requiring these procedures
while being treated with LOVENOX® (enoxaparin sodium injection) or other low-molecular-weight heparins are at
risk of developing a blood clot in or around the spine. This condition may result
in long-term or permanent paralysis.
LOVENOX® is not the same as "unfractionated heparin"
or other drugs called "low-molecular-weight heparins." Therefore, these drugs cannot
be used interchangeably with LOVENOX®.
LOVENOX® can alter the blood’s ability to clot. Patients treated with LOVENOX®,
who also have conditions affecting the clotting system, must be carefully monitored
by their physician. Adjusting the dose of LOVENOX® may be necessary for patients
who have certain forms of kidney disease. All patients receiving LOVENOX®, as
well as other anticoagulants, should be carefully monitored for bleeding by their
physician. Bleeding can occur at any site with LOVENOX® use.
Platelet drops, known as "thrombocytopenia," can occur with LOVENOX® use. Cases
of a related condition called "heparin-induced thrombocytopenia" have been observed
in clinical practice. If you have had this condition, you must notify your healthcare
professional. Your physician may perform blood tests to monitor for the occurrence
of any drop in platelet count.
The use of LOVENOX® has not been adequately studied in pregnant women with artificial
(mechanical) heart valves.
LOVENOX® should not be used in patients with an allergy or sensitivity reaction
to the active ingredient called enoxaparin sodium, heparin, or pork products, and
in patients with active major bleeding.
Common side effects include mild local reactions or irritation at the site of injection,
pain, bruising, and redness of skin.
For specific questions about your health, you should always consult your physician
or a qualified healthcare professional who is responsible for your care.
Please see
Full Prescribing Information including
boxed WARNING, for additional important
information.
Last Update:
December 2007
